Two Onc Docs: Recent Episodes
Sam and Karine
This is Sam and Karine, and we are Two Onc Docs! We both graduated from our Heme/Onc fellowship in 2021 and became board certified in both Hematology and Oncology. Our mission with Two Onc Docs is to create short board review episodes that you can listen to on your drive to work, while you make your morning coffee, or between pages on call. Each episode will include high yield facts to ace your boards.
This week’s episode will be focusing on how to approach a newly diagnosed malignancy, biopsy, staging, patient considerations ect.
This week’s episode will be focusing on how to transition well into heme/onc fellowship including differences from residency, tips for surviving, wellness, resources & more.
This week’s episode will be focusing on Diffuse Large B-Cell Lymphoma (DLBCL). We will go all the important details on this aggressive NHL which can be highly curable. We have some new changes since we last covered this topic in 2022 including a new category 1 option for advanced DLBCL
This week’s episode we are back with our very special guest, friend and colleague Dr Laura Vater joining us to talk about wellness in oncology, and burnout prevention tips.
This week’s episode we have a very special guest, friend and colleague Dr. Laura Vater joining us to talk about one of the biggest transitions in medicine—moving from fellow to attending.
Dr Vater is a GI oncologist at IU, writer, and speaker. She focuses on the dignity of patients and clinicians, and strives to keep healthcare human.
This week’s episode will be focusing on an ASCO 2026 Plenary abstract, SARC 041. SARC041 is the first positive phase 3 randomized controlled trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS), demonstrating that abemaciclib significantly improves progression-free survival compared to placebo.
Today we are recapping exciting GU data presented at the 2026 ASCO Annual Meeting in bladder cancer, kidney cancer, and prostate cancer.
This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial.
The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) metastatic pancreatic ductal adenocarcinoma (mPDAC).
Today we will be focusing on exciting data to come at the ASCO Annual Meeting in 2026 in Chicago, with a special focus on GU sessions, educational sessions & med ed sessions.
This week’s episode will be focusing on Von Willebrand disease (VWD), a highly testable bleeding disorder. We will go over all the important details on the diagnosis, types of VWD as well as treatment.
Today’s episode is focusing on the highest yield facts about Aplastic Anemia. This will include the mechanism of AA, diagnostic work-up, treatment of AA, and the evolution of clones including PNH.
Today’s episode is focusing on what you need to know regarding metastatic bladder cancer, with 2026 updates. This will include the need to know treatment options and toxicities for metastatic urothelial carcinoma, and also discuss the management of upper tract + variant non-urothelial histology.
Today’s episode is focusing on what you need to know regarding localized bladder cancer, with 2026 updates. This will include the need to know pathology, presentation, diagnostic work-up, staging, and treatment options.
This week’s episode will be focusing on how we met, the future of the podcast, and why we picked heme/onc. This is a very different style of episode and a special once because this month is our 4 year anniversary of Two Onc Docs! And we will back to our regular programming next week with overdue updates on Bladder Cancer.
We are back with a very special guest Dr. Michael Pishvaian, who is an Associate Professor in GI Oncology at the Johns Hopkins Kimmel Cancer Center, and creator of Tumor Board Tuesday. In part 3, we discuss supportive care in pancreatic cancer, and exciting trials in this space.
We are back with a very special guest Dr. Michael Pishvaian, who is an Associate Professor in GI Oncology at the Johns Hopkins Kimmel Cancer Center, and creator of Tumor Board Tuesday. In part 2, we will focus on metastatic pancreatic cancer, 1L treatments, maintenance therapy, targeted therapy + more.
This week’s episode will be discussing Pancreatic Cancer with a very special guest Dr. Michael Pishvaian. Dr. Pishvaian is an Associate Professor in GI Oncology at the Johns Hopkins Kimmel Cancer Center, and creator of Tumor Board Tuesday. In part 1, we will focus on risk factors, diagnosis and treatment of localized pancreatic cancer.
This week’s episode will be focusing on a recap of some of the important data ASCO GU just held in San Francisco end of February. We will go over some topics in prostate, RCC, bladder cancer, and other GU tumors.
This week’s episode will be focusing on Neuroendocrine Tumors (NET). We will go over all the important details regarding the heterogeneous group of NETs, diagnosis, work-up, treatment, and focus mostly on gastro-entero-pancreatic NETs.
This week’s episode we are back with our special guest & thrombosis expert Dr. Marc Carrier. In part 2, we discuss additional special considerations like IVC filter indications, and management of VTEs in the setting of thrombocytopenia. We also discuss VTE prevention in patients with cancer, the Khorana score, exciting research to come in this space, and career advice.
This week’s episode will be focusing on a very important topic, with our special guest Dr. Marc Carrier. Dr. Carrier is a Professor in the Faculty of Medicine, and holds a Tier 1 Clinical Research Chair in Venous Thromboembolism and Cancer from the Faculty of Medicine at the University of Ottawa. We discuss the work-up and treatment of VTEs and cancer, including types of anti-coagulation, duration, and special considerations.
This week’s episode we discuss what to look forward to at ASCO GU this week. Held in SF Feb 26-28 in San Francisco. We will go over the program in prostate cancer, kidney cancer, bladder cancer, as well as testicular cancer.
This week’s episode, we are back with our special guest Dr. Ria Kraft, a radiation oncologist and host of Rad Onc Talks. In part 2, we go over important details on duration + fractionation schemes, indications for palliative RT, other indications for RT in metastatic disease, and more.
This week’s episode will be focusing on basics of radiation oncology. We are so excited to welcome a special guest Dr. Ria Kraft, who has a YouTube channel called Rad Onc Talks for radiation oncology education. In part 1, we go over important details on types of radiation, how it works, the patient experience, common side effects and more.
This week’s episode we are so excited to welcome Dr. Chadi Nabhan, who is a hematologist and medical oncologist, author, and host of Healthcare Unfiltered. We discuss why oncology, our career paths, different career paths in hematology and oncology, contract & negotiation considerations, as well as tips to search for a job.
This week’s episode is a new topic! We will be focusing on basics of nutrition in oncology. We are so excited to welcome a very special guest Dr. Krystle Zuniga, who is a board-certified specialist in oncology nutrition.
In part 2, we will go over dietary strategies focusing on cancer prevention, and myths around what causes cancer.
This week’s episode is a new topic! We will be focusing on basics of nutrition in oncology. We are so excited to welcome a very special guest Dr. Krystle Zuniga, who is a board-certified specialist in oncology nutrition.
In part 1, we will go over information + myths in oncology nutrition including cancer feeds sugar, fiber, estrogen, supplements, fasting, and more.
Happy New Year! This week’s episode will be focusing on 2026 update for Follicular Lymphoma. We will go over the important details on the diagnostic criteria, indications for treatment and types + toxicities of treatment.
This week’s episode will be focusing on an update of a late-breaking abstract presented at ASH 2025 this past week: the Phase 3 BRUIN-CLL 313 trial looking at Pirtobrutinib vs Bendamustine/Rituximab in 1L Chronic Lymphocytic Leukemia (CLL).
This week’s episode will be focusing on gastrointestinal stromal tumors, known as GIST with a 2025 update. We will go over important details on the diagnosis, mutations, and treatment of local and metastatic GISTs.
This week’s episode is also due for an update since it aired in 2022. Will be focusing on Hodgkin Lymphoma (HL), both classical and nodular lymphocyte-predominant. We will go into important details on the pathology, staging, Deauville scoring, and treatment for early stage/advanced stage as well as relapsed and refractory HL.
Today’s episode is focusing on what you need to know regarding Anal cancer. This was one of our first episodes back in 2022 so it is time for an updated episode! This will include the important details on risk factors, diagnostic work-up, staging and treatment of both localized and metastatic anal cancer.
This week’s episode will be on many exciting updates were announced at ESMO this October in Berlin from Oct 17-21, 2025, especially in bladder cancer, we continue to make such progress! We discuss key trials in NMIBC (POTOMAC), MIBC (KN-905, IMvigor-011), and metastatic urothelial carcinoma (FORAGER-1, DV + Toripalimab).
This week’s episode will be focusing on details of the hematology & oncology board exams, how we prepared the days leading up to our exam, and we cover some highly tested topics in both hematology & oncology. We wish the best of luck to everyone taking their boards this year!
This week’s episode will be focusing on Porphyrias…which is very timely since this week is HALLOWEEN and porphyrias are the diseases many people believe started the vampire legend!
This week’s episode is part 3 of our breast cancer series, with a 2025 update focusing on metastatic breast cancer systemic therapies, toxicities, and supportive care considerations.
This week’s episode will be focusing on treatment options for localized breast cancer with 2025 updates. We will go over important details on indications for adjuvant radiation, as well as therapies based on the ER/PR/HER-2 receptor status.
October marks Breast Cancer Awareness Month. We are providing 2025 update for our 3 part breast cancer episodes, in part 1 today we cover an introduction on breast cancer screening, prevention.
This week’s episode will be focusing on Esophageal and Gastrosophageal Junction (GEJ) Cancer. We will go over important details on the risk factors, diagnosis, and treatment for both localized and metastatic esophageal cancer.
This week’s episode will be focusing on Immune Thrombocytopenia Purpura ( ITP). We will go all the important details on causes, mechanism, diagnosis and treatment. The last time we covered this topic was in Sept 2022, and this comes up ALL the time in heme consults, and there will definitely be board review questions. It may also be tested on IM boards.
This week’s episode will be an update on Bone Sarcomas. We will go over the important details on diagnosis, staging, subtypes and treatment of a few bone sarcomas. Just like Soft Tissue Sarcomas, these are RARE tumors encompassing 1% of all adult cancers and having multiple subtypes. They are more common in children, and most of our bone sarcoma recommendations that are testable are based on pediatric data.
This week’s episode will be focusing on soft tissue sarcomas. We last recorded this topic in 2023, and well we have some new FDA approvals and updates since then.
We will go over the important details on the diagnosis, subtypes and treatment of a few soft tissue sarcomas. These are RARE tumors encompassing 1% of all adult cancers and having multiple subtypes that range from noncancerous tumors such as desmoid tumors to aggressive cancers and everything in between.
Today’s episode will focus on an update for commonly tested Thrombotic microangiopathies (TMA) such as Thrombotic Thrombocytopenic Purpura (TTP). This will include the high yield facts on mechanism, presentation, diagnostic work-up, and treatment of TTP, and also discuss Hemolytic Uremic Syndrome (HUS), and atypical HUS.
This week’s episode will be focusing on Gastric Adenocarcinoma. We will go over all the important details on risk factors, diagnostic work-up, staging and treatment for both local regional disease and metastatic disease with updates in 2025 since we last covered this topic in 2023.
We are updating another important GYN ONC topic: endometrial (uterine) cancer. We will go over all the important details on the risk factors, presentation, diagnosis, staging & treatment options. We will also cover rare uterine malignancies at the end of the episode.
Today’s episode we will cover 2025 updates for metastatic renal cell carcinoma. We will discuss risk categories, treatment options, and variant histologies. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!
Today’s episode we will cover 2025 updates for localized renal cell carcinoma (RCC) with Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos! We will discuss risk factors, the presentation, staging, and treatment options.
This week’s episode will be focusing on Cervical Cancer with some updates since we last released this topic in 2022. We will go over important details on prevention, risk factors, diagnosis & treatment.
This week’s episode is an update on a must-know topics both for new fellows & residents. We will go over clinically important oncologic emergencies including brain metastases, hypercalcemia of malignancy, cord compression and SVC syndrome.
This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.
This week’s episode will be focusing on how to prepare for the start of heme/onc fellowship!
We will go over some general advice on how to succeed, study tips and resources we used throughout fellowship as well as some tips on how to stay academically productive during training if you are planning for an academic career.
This week’s episode will be focusing on one of the 2025 plenary sessions: SERENA-6, Camizestrant, a novel selective estrogen receptor degrader (SERD) + CDK 4/6i for tx of emergent ESR1 during 1L endocrine-based therapy + ahead of progression in stage 4 HR+/Her-2 negative breast cancer.
We discuss the trial design, endpoints, results, safety concerns, and how it fits into current practice.
This week’s episode will be focusing on Ovarian Cancer with 2025 updates since we last covered this topic in 2022. We will go over all important details on the risk factors, presentation, diagnosis, staging & treatment options for both localized and metastatic disease.
This week’s episode will be focusing on exciting data in GU presented at the 2025 ASCO Annual Meeting in prostate (including prognostication of PSA response in mCSPC, AMPLITUDE - PARPi in mCSPC), RCC (including updates in KN-564, CM-214 and PDIGREE), and finally bladder CA (with updates in NIAGARA and EV-302) among others.
This week’s episode will be focusing on exciting data to come at the ASCO Annual Meeting 2025 starting with the plenary sessions, then a special focus on the GU abstracts, including prostate CA, renal cell carcinoma, bladder CA, and a quick shout-out for some of the medical education sessions.
This week’s episode will be focusing on hepatocellular carcinoma (HCC). We will go over important details on assessing liver function, staging of HCC and loco-regional as well as systemic treatment options for HCC.
This week’s episode will be focusing on Hematopoietic Stem Cell Transplant. We welcome our guest Dr. Jeff Auletta, Senior Vice President, National Marrow Donor Program, and Chief Scientific Director,Center for International Blood and Marrow Transplant Research. Part 2 discusses conditioning regimens, graft-vs-host disease, toxicities, and Dr. Auletta's career path.
This week’s episode will be focusing on Hematopoietic Stem Cell Transplant. We welcome our guest Dr. Jeff Auletta, Senior Vice President, National Marrow Donor Program, and Chief Scientific Director,Center for International Blood and Marrow Transplant Research. Part 1 discusses important basics including what a transplant is, types of transplant & associated risks, types of donors, how to find a donor, and barriers/inequities of finding a donor.
This week’s episode is part 2 of testicular cancer 2025 updates. We had the honor of interviewing Dr. Larry Einhorn a true legend when it comes to the management of non-seminoma last year, released 4/22/2024, but today, we will be repeating a quick overview of the staging and management for initial treatment of non-seminoma as well as refractory disease.
This week’s episode is part 1 of testicular cancer 2025 updates. We had the honor of interviewing Dr. Larry Einhorn a true legend when it comes to the management of testicular CA last year, released in April 2024, but today, we will be repeating a quick overview of risk factors and staging for testicular cancer, as well as the management of seminoma.
This week’s episode will be focusing on an update of CLL. We will go over important details on the presentation, diagnosis, prognostic factors, and treatment options for initial and refractory disease, as well as key toxicities.
We are so excited to welcome back Dr. Charles (Chuck) Ryan for our 2025 prostate cancer updates. Dr. Ryan is an internationally recognized GU oncologist and prostate cancer expert, seeing patients at MSK in NYC, and co-host of the podcast 'The Good News About Cancer'.
This episode will cover metastatic prostate cancer including board review pearls & key toxicities of treatments, upcoming exciting research in PCa, and advice for trainees/early career faculty.
We are so excited to welcome Dr. Charles (Chuck) Ryan for our 2025 prostate cancer updates. Dr. Ryan is an internationally recognized GU oncologist and prostate cancer expert, seeing patients at Memorial Sloan Kettering in NYC.
This episode will cover localized prostate cancer, risk factors, staging, role of PET PSMA, risk stratification, treatments, as well as introduce biochemical recurrence.
Today’s episode is focusing on what you need to know regarding metastatic colon cancer. This will include the need to know about molecular studies, treatment, and surgery for oligometastatic disease. There has been three breakthroughs since we last covered this topic in the treatment of metastatic CRC based on molecular findings that we will go over today.
Today’s episode is focusing on what you need to know regarding early stage colorectal cancer (CRC) as of 2025. The last time we covered this topic was in 2023 and things continue to change. We will go over all the important details on the diagnosis, presentation, diagnostic work-up, role of ctDNA, staging, treatment, and surveillance of localized CRC.
We are so honored to welcome back Dr. S. Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. He is also Editor-In-Chief of Blood Cancer Journal and the Chairperson of the Board of the International Myeloma Foundation. This week’s episode will be focusing on additional pearls for the treatment of Multiple Myeloma including options for refractory disease, as well as advice for trainees.
Today we will be discussing a few of the exciting abstracts presented at ASCO GU (Feb 13-15 2025) for prostate CA (TALAPRO-2), bladder CA (EV-302, CM-274, NIAGARA), and RCC (COSMIC-313, KIM-1).
Today we will be discussing exciting data to come at ASCO GU (Feb 13-15 2025) in terms of research for prostate CA, bladder CA, RCC and other rarer GU tumors.
We are so honored to welcome Dr. S. Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. He is also Editor-In-Chief of Blood Cancer Journal and the Chairperson of the Board of the International Myeloma Foundation. This week’s episode will be focusing on Multiple Myeloma symptoms, diagnostic criteria, work-up and initial treatment.
This week’s episode will be focusing on additional details for Extensive Stage Small Cell Lung Cancer (SCLC), options for relapsed/refractory disease & advice for trainees. We are so excited to welcome back Dr. Stephen Liu international expert for lung cancer, Director of Thoracic Oncology & Developmental Therapeutics at Georgetown Lombardi Cancer Center and Co-Host of the IASLC Podcast.
This week’s episode will be focusing on Small Cell Lung Cancer (SCLC). We will go all the important details on risk factors, diagnostic work-up, staging and treatment of both locoregional and metastatic SCLC. We are so excited to welcome Dr. Stephen Liu international expert for lung cancer, Director of Thoracic Oncology & Developmental Therapeutics at Georgetown Lombardi Cancer Center and Co-Host of the IASLC Podcast.
This week’s episode will be re-discussing one of the myeloproliferative neoplasms, Polycythemia Vera (PV). We will go over the important details on the diagnosis, risk stratification for thrombus and treatment.
Happy New Year! This week’s episode will go over important details related to immune checkpoint inhibitors (ICIs) and immune-related adverse events (irAEs), with general management strategies for each of the most common iRAEs.
This week’s episode will be focusing on advanced Thymoma and Thymic Carcinoma, board review pearls, and career advice for trainees & early career oncologists. We are back with Dr. Pat Loehrer, who is a legend when it comes to the treatment of Thymoma.
This week’s episode will be focusing on localized Thymoma and Thymic Carcinoma. We are so honored to have Dr. Pat Loehrer here with us today who is a legend when it comes to the treatment of Thymoma. He is a Distinguished Professor of Medicine Joseph W. and Jackie J. Cusick Professor of Oncology, Director for Center of Global Oncology and Health Equity and prior cancer center director at Indiana University.
This week’s episode will be focusing on Metastatic Non-small Cell Lung Cancer (NSCLC). We are back with Dr. Jennifer Marks, Thoracic Oncologist at the Dana-Farber Cancer Institute. We will go all the important details on the quickly growing and changing systemic therapy options including traditional chemotherapy, immunotherapy and targeted agents
This week’s episode will be focusing on Localized Non-small Cell Lung Cancer (NSCLC). We are very excited to have Dr. Jennifer Marks with us today. Dr. Marks is a thoracic oncologist at the Dana-Farber Cancer Institute, Instructor in Medicine at Harvard Medical School, who also recently took her oncology boards. We will go all the important details on basic of staging, treatment for resectable and unresectable localized NSCLC, and updates in terms of peri-operative and targeted therapies
This week’s episode will be focusing on Hemoglobin (Hb) electrophoresis. We will go important details on what Hb electrophoresis is, the normal breakdown of adult hemoglobin, and specific hemoglobinopathies (thalassemias, sickle cell, Lepore...) you can be tested on during your ITEs and hematology boards.
In honor of National Family Health History Month in November, we have a special guest. We share the story of an incredible colorectal cancer survivor and health advocate, Marisa Peters, who was a Broadway vocalist and a very healthy, active mom to 3 young boys, yet diagnosed with stage 3 rectal cancer at only 39 years old.
This week’s episode is part 3 of 2024 updates focusing on treatment options for metastatic breast cancer. We will cover important details on systemic therapy related to metastatic breast cancer & key toxicities.We are honored to have Dr. Eleonora Teplinsky, a board-certified medical oncologist specializing in breast and gynecologic oncology, as a guest sharing some pearls.
This week’s episode is part 2 of 2024 updates focusing on treatment options for localized breast cancer. We will discuss important details on radiation, as well as therapies based on ER/PR/her2 receptor status. We are honored to have Dr. Eleonora Teplinsky, a board-certified medical oncologist specializing in breast and gynecologic oncology, as a guest sharing some pearls.
We are continuing our 2024 updates, this week’s episode will be an intro to breast cancer. Today’s will include high yield tips on screening, prevention, ductal carcinoma in situ DCIS, lobular carcinoma in situ LCIS, as well as introduce invasive localized disease.
This week’s episode will be discussing our favorite heme/onc board review resources. This is pertinent to new fellows who are starting to think about how to study during fellowship, preparation for ITEs and of course studying for the boards.
We are doing a special episode this week to cover some of the key GU abstracts from ESMO 2024. We cover an update on the STAMPEDE prostate cancer trial, SUNNIFORECAST in non-clear cell renal cell carcinoma, SunRISe-4 in bladder cancer, and more.
In Part 2 we discuss how to deal with patients of different backgrounds, navigating spiritual & emotional challenges in oncology, tips for physicians who are experiencing moral distress & compassion fatigue, as well as general career advice. We are so honored to have Dr. Janet Abrahm with us who is a national leader in the field of palliative care and a professor at Harvard Medical School.
This week’s episode will be focusing on final board review tips. We will go over our highest yield cheat sheet topics, and how we prepared the days leading up to our exam. We took our boards three years ago now, but the stress leading up to the exam is certainly fresh in our minds.
In Part 1 we discuss how to explain palliative care to patients, pain and anti-emetic management, non-pharmacologic strategies, and current innovations within palliative care. We are so honored to have Dr. Janet Abrahm here with us who is a national leader in the field of palliative care and a professor at Harvard Medical School.
This week’s episode will be repeating our episode on hemophilias with some updates. We will go over all high yield facts regarding both hemophilia A and B for your boards and end with a little bit about acquired hemophilias.
This week’s episode will be discussing updates from ASCO 2024 next with the practice changing NADINA trial presented on the Sunday of ASCO by Dr. Christian Blank during the plenary sessions: A multicenter, randomized, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. We discuss the staging and prior standard of treatment for locally advanced melanoma, key findings from NADINA, and how these data may impact clinical practice.
Today’s episode is a continuation on fast facts for the IM Board review focusing on the oncology questions. Another 6% of the certifying ABIM test is oncology. While we can’t cover ALL of oncology in just 10 minutes, here are 10 high yield concepts/facts/vignettes you should know walking into your IM Boards.
Today’s episode focuses on what you need to know to ace the hematology questions for your 2024 IM boards. 6% of the ABIM exam is hematology which includes erythrocyte, leukocyte and platelet disorders, coagulation disorders, transfusion medicine, and heme malignancies. We discuss some common vignettes & high yield points.
This week’s episode will be focusing on infusion reactions - one of the most common calls we get as heme/onc fellows and high yield facts for new fellows as well as boards. We will go over the important details on mechanisms of infusion reaction, class of drugs that most commonly cause infusion reactions, treatment for infusion reactions, and when/how to re-challenge.
This week’s episode will be focusing on common topics both for new fellows & residents. We will go over the important details on some clinically important oncologic emergencies including brain metastases, hypercalcemia, cord compression and SVC syndrome.
This week’s episode will discuss updates from ASCO 2024 next with the practice changing ADRIATIC trial presented by Dr. Spigel during the plenary: Durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer (LS-SCLC).
In light of the new academic year today, we are so excited for this special episode, hosting Dr Shikha Jain, who is the founder of Women in Medicine & a GI oncologist, & involved with ASCO Women's Networking Center. She shares some of her tips for new doctors, and a few for new attendings.
Today’s episode is an update on AML (acute myeloid leukemia). In Part 2 we discuss the treatment options for first-line, as well as relapsed/refractory disease. We are so honored to have Dr. Catherine Lai here with us who is Associate Professor and Physician Leader of the Leukemia Clinical Research Unit at UPenn.
Today’s episode is an update on AML (acute myeloid leukemia). In Part 1 we discuss the usual presentation, diagnostic work-up, and updates on the classification of AMLs. We are so honored to have Dr. Catherine Lai here with us who is Associate Professor and Physician Leader of the Leukemia Clinical Research Unit at UPenn.
This week’s episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam.
Today’s episode is updating what you need to know regarding the treatment of metastatic melanoma. We are so honored to have Dr. Michael Atkins here with us today, who is the first author of the practice changing DREAMseq trial, and provides his expertise on this important topic.
Today’s episode is a 2024 update on what to know regarding the risk factors, diagnostic work-up, staging and treatment of localized melanoma. We are so honored to have Dr. Michael Atkins here with us today who is deputy director of the Georgetown Lombardi Comprehensive Cancer Center . He is an internationally recognized expert in the management of patients with high-risk and metastatic melanoma or kidney cancer.
This week’s episode will be focusing on the second part of genetic syndromes with risk of malignancy. Last week we covered Li Fraumeni, Lynch, FAP, BRCA ½ and Cowdens. This week we are going to cover the syndromes associated with RCC as well as MEN 1 and 2 and a few others.
This week’s episode will be focusing on genetic syndromes with increased risk of malignancies. In Part 1 we discuss Li-Fraumeni, Lynch Syndrome, FAP, BRCA 1 and 2, and Cowden's syndrome.
Today’s episode we will cover 2024 updates for metastatic renal cell carcinoma. We will discuss risk categories, treatment options, and variant histologies. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!
Today’s episode we will cover 2024 updates for localized renal cell carcinoma (RCC). We will discuss risk factors, the presentation, staging, and treatment options. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!
This week’s episode will be focusing on Testicular Cancer, including the treatment of Non-Seminomas. We are so honored to have Dr. Larry Einhorn here with us today and he provides key pearls, in addition to words of wisdom for trainees in oncology.
This week’s episode will be focusing on the risk factors, work-up, and staging of Testicular Cancer, as well as cover the treatment of Seminomas. We are so honored to have Dr. Larry Einhorn here with us today who is a legend when it comes to the treatment of germ cell tumors, and among many other accolades is Distinguished Professor of Medicine at the University of Indiana.
This week’s episode will be focusing on hematopoietic growth factors, including G-CSF, TPO agonists, and ESAs. This is another episode in our series on supportive care, and a highly testable and frequently discussed topics on consults and in clinic.
Today marks our 2 year mark of Two Onc Docs! It’s been a while since we’ve done a re-intro so we figured we would re-introduce ourselves and explain why we picked heme/onc as a speciality, and briefly cover our study plans.
This week’s episode will be focusing on Cancer Related Fatigue (CRF). We will go over important details on the definition, diagnosis, and management options of this condition which affects >2/3 of patients with cancer.
This week’s episode will be focusing on Primary CNS Lymphoma. We will go over important details on the epidemiology, diagnosis, staging and treatment options.
This week’s episode will be focusing on cutaneous malignancies other than melanoma including squamous cell skin cancer and basal cell carcinoma. We will go over the important details on staging, diagnosis, & treatment options.
This week’s episode will be focusing on Malignant Mesothelioma. We will go over the important details on diagnosis, work-up, the different subtypes, and staging as well as treatment options for operable and inoperable disease.
We are starting a supportive care series, because these topics comes up very often in oncology. This week's episode will be focusing on Bone Modifying Agents, such as bisphosphonates and Denosumab - when they are indicated, mechanism of action, and key pearls/toxicities.
This week’s episode will be focusing on acquired causes of underproduction anemias. We will go over the important details on iron deficiency, vitamin B12 and folate deficiencies as well as anemia of chronic disease, anemia of pregnancy, and a few other rarer causes of underproduction anemias. This topic will come up time and time again during consults, clinic and of course on test day.
This week’s episode will be focusing on occult cancers, or cancers of unknown primary (or CUP). We will go over the important details on the work-up, diagnostic markers, molecular testing, as well as treatment options.
This week’s episode will be focusing on Mantle Cell Lymphoma. We will go over the important details on the presentation, diagnosis and treatment.
This week’s episode will be focusing on a rare tumor: Adrenocortical Carcinoma. We will go over the important details on the presentation, diagnosis and treatment.
Happy 2024 and welcome to our THIRD season of Two Onc Docs! This week’s episode will be focusing on Hairy Cell Leukemia, we will cover important details on the symptoms, diagnosis and treatment of hairy cell leukemia.
Today’s episode we will cover 2023 updates for metastatic bladder cancer. We will discuss staging, treatment options (with EV-302 groundbreaking updates), and variant histologies. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!
Today’s episode we will cover 2023 updates for localized bladder cancer. We will discuss the presentation, diagnostic work-up, staging, and treatment options. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!
This week’s episode will be focusing on one of the Non-Hodgkin Lymphomas: Follicular Lymphoma. We will go over the important details on diagnostic criteria, indications for treatment and treatment options.
This week we are updating our Metastatic Non-Small Cell Lung Cancer episode. We will cover important details on the quickly growing and changing systemic therapy options including traditional chemotherapy, immunotherapy and targeted agents.
This week’s episode is our 2023 update of the treatment landscape of early stage and locally advanced Non-Small Cell Lung Cancer (NSCLC). We will cover important details on pathology, staging, local and systemic therapy options, and special scenarios.
This week’s episode will be focusing on some of the most testable thrombophilia syndromes including Antiphospholipid Syndrome, Antithrombin III deficiency, Protein C and S deficiency, Factor V Leiden, and Prothrombin mutations. We will go over important details on the presentation, diagnostic testing, and treatment.
This week’s episode is a 2023 update focusing on metastatic breast cancer. We will cover important details on systemic therapy related to metastatic breast cancer & key toxicities.
This week’s episode is part 2 of 2023 updates focusing on treatment options for localized breast cancer. We will discuss important details on radiation, as well as therapies based on ER/PR/her2 receptor status.
We are continuing our 2023 updates, this week’s episode will be an intro to breast cancer. Today’s will include high yield tips on screening, prevention, ductal carcinoma in situ DCIS, lobular carcinoma in situ LCIS, as well as introduce invasive localized disease.
This week’s episode is a quick one, focusing on heparin induced thrombocytopenia (HIT). We will go over the the pathophysiology, diagnosis and treatment of HIT.
This week’s episode will be focusing on Hematopoietic Stem Cell Transplant. We will go over the important details on the different types of SCT, where stem cells can be collected from, conditioning regimens as well as complications to be aware of for boards. This is a robust field so remember by no means is this short episode all of SCT but rather a quick overview for highest yield information for boards
Today’s episode is covering the treatment options for M0 castrate resistant prostate cancer as well as metastatic castrate-sensitive and castrate-resistant prostate cancer, including some 2023 updates.
We are diving into 2023 updates on our 2 part episode on localized and metastatic cancer. This episode will cover localized prostate cancer, as well as introduce biochemical recurrence.
Today’s episode is a 2023 update on the management of metastatic colon cancer. This will include an overview of molecular studies, treatment options and their toxicities.
Today’s episode is a 2023 update on what you need to know regarding early stage colon cancer. We will go over all the important details on the diagnosis, presentation, diagnostic work-up, staging, treatment, and surveillance.
This week’s episode will be focusing on hemolytic anemia. We will primarily focus on acquired forms of hemolytic anemia which include warm autoimmune hemolytic anemia (WAIHA), cold agglutinin disease (CAD), paroxysmal cold hemoglobinuria (PCH), and briefly cover a few other key differentials.
This week’s episode will be focusing on inherited platelet disorders We will go over the important details on the roles of platelets, platelet parts as well as the diagnosis of inherited platelet disorders through aggregation studies as well as the treatment of these disorders.
This week’s episode will be focusing on one more of the myeloproliferative neoplasms, Primary Myelofibrosis (PMF). We will go over important details on the diagnosis, risk stratification and treatment options.
This week’s episode will be focusing on Esophageal and Gastrosophageal Junction (GEJ) Cancers. We will go over high yield details on the risk factors, diagnosis, and treatment for both localized and metastatic esophageal cancer.
This week’s episode will be focusing on another one of the myeloproliferative neoplasms (MPN): Polycythemia Vera (PV). We will go over the important details on the diagnosis, risk stratification, and treatment.
This week’s episode is part 2 of our series in honor of Sarcoma Awareness Month. We will be focusing on Bone sarcomas. We will go over the important details on diagnosis, staging, subtypes and treatment of a few highly testable bone sarcomas.
Since July is Sarcoma Awareness Month, we are starting a 2-part series on sarcomas. This week’s episode will be focusing on soft tissue sarcomas. We will go over the important details on the diagnosis, subtypes and treatment of a few of the highly testable soft tissue sarcomas.
This week is the final episode of a joint mini-series with The Fellow On Call. We will be recapping the current treatment of localized ER+/HER-2- breast cancer and covering an oral abstract from the ASCO 2023 annual meeting, the NATALEE Trial. We also cover some more statistics pearls that are important in oncology trials.
This week’s episode is part 3 of 5 of a joint mini-series with The Fellow On Call. We will be recapping the current treatment of metastatic renal cell carcinoma (mRCC) and covering an oral abstract from the ASCO 2023 annual meeting, the CONTACT03 Trial. We also cover subgroup analysis interpretation.
This week’s episode is part 1 of 5 of a joint mini-series with The Fellow On Call. We will be recapping the current treatment of locally advanced rectal cancer and covering a plenary session abstract from the ASCO 2023 annual meeting, the PROSPECT Trial. We also cover the concept of non-inferiority trials.
This week’s episode will be focusing on the diagnosis and treatment of rectal cancer. We will go over important details on the diagnosis, staging and treatment of both locally advanced and metastatic rectal cancer.
ASCO 2023 is just around the corner and we are teaming up with The Fellow On Call to bring you a joint mini-series called “Paging Heme/Onc: Updates from ASCO 2023” where we’ll bring you brief, high-yield discussions of some of the research we found most interesting from this year’s conference.
This week’s episode is part 2 of our series focusing on transfusion medicine. We discuss indications for pre-transfusion protocols, as well as infectious and non-infectious, and acute & delayed risks of transfusions
This week’s episode is part 1 of a 2 part series focusing on transfusion medicine. In part 1, we cover important details on blood group systems, blood components, indications for these components, and quickly cover apharesis.
This week’s episode will be focusing on thyroid cancers. We will go over details on the staging, breaking down the various types of thyroid cancers and of course the treatments for this disease group.
This week’s episode is part 2 of our plasma cell dyscrasias series. We will go over the important details on risk stratification, as well as initial and relapse treatment options for Multiple Myeloma, with key details on the pharmacology of myeloma drugs.
This week’s episode will be an introduction to plasma cell dyscrasias. We will cover the diagnostic criteria for MGUS and Smoldering Myeloma as well as introduce Multiple Myeloma.
Today we tackle inheritable bone marrow failure syndromes. We will go over the important details on the various types of testable bone marrow failure disorders including the key features of diagnosis and treatment.
This week’s episode will be focusing on cholangiocarcinoma, or biliary tract cancer. We will go over the testable high yield facts on the risk factors, diagnosis, and treatment of local and advanced cholangiocarcinoma.
This week’s episode will be focusing on syndromes of iron overload. We will go over important details on hemochromatosis and other related diseases, as well as iron chelation.
This week’s episode will be focusing on how we met, the future of the podcast, and different career paths in hematology and oncology. This is a very different style of episode and a special once because today is our one year anniversary of Two Onc Docs! We will back to our regular programming next week.
This week’s episode will be focusing on one of the myeloproliferative neoplasms, Essential Thrombocythemia (ET). We will go over the important details on the diagnosis, risk stratification, and treatment.
This week’s episode will be discussing Pancreatic Cancer. We will go over testable facts on the epidemiology, diagnosis, and treatment of both localized & metastatic pancreatic adenocarcinoma.
This week’s episode will be focusing on Sickle Cell Anemia. We will go over important details on sickle cell diseases including the pathophysiology , diagnosis and treatment of this group of diseases.
This week’s episode will be focusing on gastric adenocarcinoma. We will go high yield testable facts on the risk factors, diagnostic work-up, staging and treatment for both local regional disease and metastatic gastric cancers.
This week’s episode will be discussing chimeric antigen receptor modified T cell (CAR-T) immunotherapy. We will go over important details on what it is, how it works, when it is used, and key toxicities.
This week’s episode will be focusing on alpha thalassemia. We will go over details on the pathophysiology, symptoms, diagnosis and treatment of alpha thalassemia variants.
This week’s episode will be focusing on hepatocellular carcinoma (HCC). We will go over high yield facts on the staging, and treatment options for both locoregional and advanced HCC.
This week’s episode will be focusing on head & neck cancers. We will go over high yield testable facts on the epidemiology, diagnosis, staging and treatment of head & neck cancers.
This week’s episode will be focusing on Beta Thalassemias. We will go over all the quick facts on normal hemoglobin composition, as well as the diagnosis and treatment of beta thalassemia minor, intermedia and major.
This week’s episode will be focusing on Acute Lymphoblastic Leukemia (ALL). We will go over quick facts on the diagnosis, prognostic factors, and treatment options for both B-cell & T-cell acute lymphoblastic leukemias.
This week’s episode will be focusing on gastrointestinal stromal tumors, known as GIST. We will go over all the important details on the diagnosis, mutations, and treatment of local and metastatic GISTs for health care providers.
Since this is something we are often asked, in this week’s episode will be discussing our favorite heme/onc board review resources for those in hematology/oncology fellowship.
Happy 2023! In this week’s episode we kick off Season 2 with a re-introduction and an explanation of why we picked hematology/oncology as a speciality (& why we both love what we do).
Today’s episode will be focusing on primary brain tumors within neuro-oncology. We will primarily be discussing the classification of gliomas and management, including oligodendrogliomas, ependymomas, astrocytomas, and glioblastoma multiforme (GBM).
This week’s episode will be focusing on Chronic Lymphocytic Leukemia (CLL) for health care providers. We will go over all the important details on presentation, diagnosis, prognostic factors, and treatment options.
This week’s episode will be focusing on neuroendocrine tumors (NET), their characteristics, diagnosis, associated syndromes, and focus mostly on gastro-enteropancreatic NETs.
This week’s episode will be focusing on a bleeding disorder, Von Willebrand disease (VWD). We will go over all the important details on the diagnosis, types of VWD (& ways to remember them!) as well as treatment options.
This week’s episode will be focusing on Cervical Cancer facts for health care providers. We will go over important details on prevention, risk factors, diagnosis & NCCN category 1 treatments.
This week’s episode will be focusing on porphyrias, we will go over quick facts on the need to know facts regarding acute & chronic porphyrias from presentation to treatment.
This week’s episode will be focusing on Chronic Myeloid Leukemia or CML for health care providers. We will go all the important details on the genetics of CML, diagnosis and treatment algorithms.
October marks Breast Cancer Awareness Month & this week’s episode is the last of 3 episodes covering breast cancer facts for health care providers. We will go over the NCCN guidelines for systemic therapy related to metastatic breast cancer, as well as common side effects of these therapies.
October marks Breast Cancer Awareness Month & this week’s episode is part 2 of 3 covering breast cancer facts for health care providers. This will summarize treatment options for localized breast cancer. We will go over important details on indications for radiation, as well as systemic therapies based on the ER/PR/her-2 receptor status.
October marks Breast Cancer Awareness Month & this week’s episode is the first of 3 episodes covering breast cancer facts for health care providers. Today’s episode will include a quick overview on breast cancer screening, prevention & hormone therapy (as well as side effects), ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), as well as introduce invasive localized disease.
This week’s episode will be focusing on Immune Thrombocytopenia Purpura ( ITP). We will go all the important details on causes, mechanism, diagnosis and treatment.
This week’s episode will be focusing on diffuse large B-cell lymphoma (DLBCL). We will go over the important category 1 NCCN & ASH recommendations for this aggressive lymphoma.
This week’s episode will be focusing on metastatic NSCLC. We will go all the important details on the quickly growing and changing systemic therapy options including traditional chemotherapy, immunotherapy and targeted agents.
This week’s episode will be focusing on early stage and locally advanced non-small cell lung cancer (NSCLC). We will go all the important details on staging, pathology, local and systemic therapy.
September will mark Uterine Cancer Awareness Month. We will go over important details on the risk factors, presentation, diagnosis, staging & treatment options for the most common types of Endometrial (Uterine) Cancer. We will also cover less common subtypes of uterine malignancies at the end of the episode.
This week’s episode will be focusing on Hemophilias. We will go over all high yield facts regarding both hemophilia A and B for your boards and end with a little bit about acquired hemophilias.
This week’s episode will be focusing on Ovarian Cancer. We will go over all the important details on the risk factors, presentation, diagnosis, staging & treatment options for the common epithelial subtypes, with a quick overview of rarer ovarian tumors.
This week’s episode will be focusing on Hodgkin's Lymphoma (HL), both classical and nodular lymphocyte-predominant. We will go into all the important details on the pathology, staging, Deauville scoring, and treatment for early stage/advanced stage as well as relapsed and refractory HL.
This week’s episode will be focusing on Testicular Cancer. We will go all the important details on the staging, risk categories, and treatment options for both seminoma and non-seminoma, as well as early and late toxicities.
Today’s episode a continuation on fast facts for the IM Board review focusing on the oncology questions. Another 6% of the certifying ABIM test is oncology. While we can’t cover ALL of oncology in just 10 minutes, here are 10 high yield concepts/facts/vignettes you should know walking into your IM Boards.
Today’s episode will be focusing on what you need to know to ace the hematology questions on your IM boards. 6% of the ABIM exam is hematology which includes erythrocyte, leukocyte and platelet disorders, coagulation disorders, transfusion medicine, and heme malignancies. We are going to discuss some common vignettes & high yield points.
Today’s episode is part 2 of our prostate cancer series, and will focus on the important details regarding treatment options for castrate sensitive and resistant prostate cancer.
This is the first of a two part episode on prostate cancer. This episode will cover localized prostate cancer, including the diagnostic work-up, staging and treatment.
Today’s episode is focusing on the highest yield facts about Aplastic Anemia. This will include the mechanism of AA, diagnostic work-up, treatment of AA, and the evolution of clones including PNH.
This week’s episode will go over Small Cell Lung Cancer (SCLC), including the risk factors, diagnostic work-up, staging and treatment of both limited and extensive stage SCLC.
Today’s episode is focusing on what you need to know regarding myelodysplastic syndrome (MDS) - diagnosis, risk stratification and treatment options for low risk as well as high risk MDS.
Today’s episode is focusing on what you need to know regarding anal cancer - the risk factors, diagnostic work-up, staging and treatment for both local regional and metastatic disease.
This week wraps up Melanoma Awareness Week! Today’s episode is focusing on the high yield facts for melanoma - risk factors, diagnostic work-up, staging and treatment options.
Today’s episode will focus on Thrombotic Thrombocytopenic Purpura or TTP. This will include the high yield facts on mechanism, presentation, diagnostic work-up, and treatment of TTP, and also discuss Hemolytic Uremic Syndrome (HUS).
Today’s episode is focusing on what you need to know regarding kidney cancer, also known as renal cell carcinoma (RCC) - including risk factors, diagnostic work-up, staging and treatment for both localized and metastatic disease.
Today’s episode is all about AML (acute myeloid leukemia), including the usual presentation, diagnostic work-up, risk stratification (and tricks to remember these), molecular testing, and treatment options for first-line, as well as relapsed/refractory disease.
Today’s episode is focusing on stage 4 colon cancer - what you need to know about the molecular studies and treatment options/sequencing for metastatic disease.
Today’s episode is focusing on Stage 1-3 colon cancer - what you need to know about the pathology, presentation, diagnostic work-up, staging, treatment, and surveillance.
Today’s episode is focusing on immune checkpoint inhibitors, how they work, what the different types are, when they are used, and what side effects to be aware of.
Today’s episode is focusing on bladder cancer - what you need to know about the pathology, presentation, diagnostic work-up, staging, treatment, and rarer upper GU tract presentations.
Today’s episode is focusing on acute promyelocytic leukemia (APL) - the need to know chromosomal translocation, presentation, diagnostic work-up, risk stratifying, treatment, and differentiation syndrome.
Welcome to Two Onc Docs! We are Sam and Karine, two recent Heme/Onc fellowship grads, and board certified oncologists and hematologists. This episode covers how we studied for the boards, skip ahead if you want board review content.